Ultragenyx Pharmaceutical

-$1.00 (-1.23%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RARE and other ETFs, options, and stocks.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.

CEO

Emil D. Kakkis

Employees

893

Headquarters

Novato, California

Founded

2010

RARE Key Statistics

Market Cap

5.43B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

368.38K

High Today

$82.66

Low Today

$79.68

Open Price

$81.27

Volume

359.40K

52 Week High

$179.65

52 Week Low

$76.78

RARE News

Simply Wall St7h

Have Ultragenyx Pharmaceutical Inc. Insiders Been Selling Their Stock?

Anyone interested in Ultragenyx Pharmaceutical Inc. ( ) should probably be aware that the Executive VP & CFO, Mardi Dier, recently divested US$288k worth of sha

Analyst Ratings

65%

of 20 ratings

Buy

65%

Hold

30%

Sell

RARE Earnings

-$2.05

-$1.37

-$0.68

$0.00

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Oct 26, After Hours

Why Robinhood?

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. View more

Have Ultragenyx Pharmaceutical Inc. Insiders Been Selling Their Stock?

65%

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.